Sarcomatoid mesothelioma is a rare, aggressive malignancy that usually follows asbestos exposure. It is the least common subtype of mesotheliomas, following epithelial and biphasic subtypes. Pleural mesothelioma can metastasize, with the liver, kidneys, adrenal glands, and opposite lungs being the most commonly reported sites for metastasis. Metastasis of the pancreas is extremely rare, which is why the authors of this case report intend to present the case of a 78-year-old male who was found to have acute pancreatitis, most likely secondary to metastatic lesions.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11305595 | PMC |
| http://dx.doi.org/10.7759/cureus.64088 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Case report: Radiological features of a case of desmoplastic malignant mesothelioma of peritoneum.
Front Oncol
December 2024
Department of Ultrasound, Hebei Medical University Third Hospital, Shijiazhuang, Hebei, China.
Desmoplastic malignant peritoneal mesothelioma (DMPM) is an extremely rare and aggressive subtype of sarcomatoid malignant mesothelioma, originating from the mesothelial lining of body cavities. It is characterized by significant local invasiveness and poor prognosis. The nonspecific symptoms of DMPM often result in delayed diagnosis.
View Article and Find Full Text PDFReal-World Outcomes of Patients With Malignant Pleural Mesothelioma Receiving a Combination of Ipilimumab and Nivolumab as First- or Later-Line Treatment.
JTO Clin Res Rep
December 2024
Department of Medical Oncology and Hematology, Cantonal Hospital Winterthur, Winterthur, Switzerland.
Article Synopsis
- A study on the combination of ipilimumab (ipi) and nivolumab (nivo) for treating malignant pleural mesothelioma (MPM) in Switzerland revealed real-world survival and safety data, confirming its status as a standard-of-care after positive clinical trial results (CheckMate-743).
- Among the 109 patients treated from November 2017 to March 2023, the objective response rate to ipi-nivo was 21% for first-line treatment and 15% for second or further-line treatments, with median overall survival being 12.6 months for first-line and 6.9 months for second-line.
- The treatment was generally well-t
Comparison of surgical treatment and systemic chemotherapy in patients with non-epithelioid malignant pleural mesothelioma.
Asian J Surg
November 2024
Gaziantep University Şahinbey Training and Research Hospital, Department of Medical Oncology, Şahinbey, Gaziantep, Turkey. Electronic address:
Objective: This study aimed to investigate the most appropriate treatment options for patients with non-epithelioid malignant pleural mesothelioma.
Methods: We retrospectively analyzed patients with non-epithelioid malignant pleural mesothelioma who received treatment at our center.
Results: Forty-two patients were included in this study.
Intrapulmonary Biphasic Mesothelioma Misdiagnosed as Adenocarcinoma: Case Report and a Potential Diagnostic Pitfall.
Onco Targets Ther
November 2024
Department of Pathology, Guiqian International Hospital, Guiyang City, Guizhou Province, People's Republic of China.
Background: Mesothelioma is an uncommon malignant tumor with variable clinical presentations, radiological features, and morphological patterns. Mesothelioma with predominantly intrapulmonary growth presents with an insidious onset, similar radiological and even morphological features to lung cancer, and poses a diagnostic pitfall.
Case Presentation: Herein, we reported a 53-year-old female with biphasic mesothelioma misdiagnosed as poorly differentiated adenocarcinoma with focal sarcomatoid carcinoma.
Digital spatial profiling for pathologists.
Virchows Arch
November 2024
Pathology Unit, Arcispedale Santa Maria Nuova, Azienda Unità Sanitaria Locale-IRCCS di Reggio Emilia, Via Risorgimento 80, 42124, Reggio Emilia, Italy.
The advent of "omics" technologies for high-depth tumor profiling has provided new information regarding cancer heterogeneity. However, a bulk omics profile can only partially reproduce tumor complexity, and it does not meet the preferences of pathologists used to perform an in situ assessment of marker expression, for instance, with immunohistochemistry. The NanoString GeoMx® Digital Spatial Profiler (DSP) is a platform for morphology-guided multiplex profiling of tissue slides, which allows the digital quantification of target analytes in different neoplastic settings.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!